Verdict No. 3028 · Search date 2026-09-08 · Methodology v1.0
Combination of 5%-thymoquinone standardized Nigella seed oil and piperine,
does it really help with Relief of total nasal symptoms in adults with seasonal allergic rhinitis?
30-Second Summary
C
Evidence Grade C · 50 · Safety caution
The subject of this page is the Nigella-oil-plus-piperine combination, not Nigella alone.
Composition varies by product and extraction method. People who are pregnant or breastfeeding, children, those with liver or kidney disease, and anyone using glucose-, blood-pressure-, anticoagulant-, antiseizure-, or immune-modifying medicines should seek clinical advice. Small trials cannot exclude rare or long-term harms.
What the
research showsGrade C with 50 points. In a 65-man 15-day trial, TNSS changed by -3.52 with the combination versus -1.03 with placebo (P<.001). Company employee authorship and piperine prevent attribution to Nigella alone.
research showsGrade C with 50 points. In a 65-man 15-day trial, TNSS changed by -3.52 with the combination versus -1.03 with placebo (P<.001). Company employee authorship and piperine prevent attribution to Nigella alone.
What the
ads claimThe result cannot be extended to Nigella alone, women, children, or long-term prevention.
ads claimThe result cannot be extended to Nigella alone, women, children, or long-term prevention.
Useful facts when choosing a product
- This verdict applies only to the exact plant part, formulation, route, dose, population, endpoint, and comparator shown above.
- Seed powder, fixed oil, aqueous extract, ethanolic topical preparation, purified thymoquinone, and combinations are not interchangeable.
- Composition varies by product and extraction method. People who are pregnant or breastfeeding, children, those with liver or kidney disease, and anyone using glucose-, blood-pressure-, anticoagulant-, antiseizure-, or immune-modifying medicines should seek clinical advice. Small trials cannot exclude rare or long-term harms.
Chamgap Semantic Classification Code
Permanent code issued
S.nigella-oil-plus-piperine.oral.allergic-rhinitis-symptoms.relieve.placeboSupplements and nutraceuticals > Nigella oil plus piperine > Oral > Allergic-rhinitis symptoms > Relief claim > Placebo
Issued for the fixed 5%-thymoquinone standardized seed-oil-plus-piperine combination, not Nigella monotherapy. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Nigella seed oil plus piperine |
| Source or part used | Nigella sativa seed fixed oil plus Piper nigrum piperine |
| Formulation or processing | Supercritical Nigellin Amber standardized to 5% thymoquinone plus 2.5 mg BioPerine |
| Route | Oral |
| Dose | 250 mg oil plus 2.5 mg piperine twice daily |
| Duration | 15 days of treatment and follow-up |
| Population | Adult men with seasonal allergic rhinitis |
| Effect or condition | Relief of total nasal symptoms |
| Primary endpoint | Change in TNSS at day 15 |
| Comparator | Matched placebo |
| Duplicate-detection key | nigella-oil-plus-piperine|5-percent-tq-combination|oral|adult-men-seasonal-rhinitis|tnss-relief|15-days |
Gap Measurement · Verdict 3028 · C 50
What the research actually shows
A fixed combination of standardized seed oil and piperine was compared with matched placebo.
Why this is classified as C (50)
A direct placebo contrast and large TNSS change are offset by small size, 15-day duration, men only, combination attribution, and company involvement, yielding C with 50 points.
Counterpoint. Uncertainty does not prove no effect, but a signal from one formulation cannot validate another formulation or claim.
Rejudgment record. Independent Codex cross-check — One page, one route, one population, one claim, one principal comparator
Scoring profile behind this grade
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
| Precision | C0 | The confidence interval leaves room for benefit |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Efficacy and safety of a standardized Nigella sativa oil and piperine combination in seasonal allergic rhinitis | The cited controlled design and its allocation or masking limitations were independently checked. | 32 | Funding, product support, and employee authorship were assessed separately; unverified items were not counted as strengths. | The principal endpoint is defined in the exact facets; secondary outcomes remain separate. | The verified quantitative result is reported in the English reader answer and rationale without inventing missing confidence intervals. | Direct proprietary combination evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-09-08).
Majeed M et al. Standardized Nigella sativa oil with piperine for seasonal allergic rhinitis. Medicine (Baltimore). 2024. PMID: 39121267. PMCID: PMC11315530. DOI: 10.1097/MD.0000000000039243. CTRI/2022/07/044180.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Standardized Nigella Oil Plus Piperine for Seasonal Allergic Rhinitis—Positive at 15 Days, Not a Monotherapy Result — Evidence Grade C·50. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/oral-standardized-nigella-oil-piperine-seasonal-allergic-rhinitis/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.